Public-sector Contributions to Novel Biologic Drugs

Rahul K Nayak; ChangWon C Lee; Jerry Avorn; Aaron S Kesselheim

doi:10.1001/jamainternmed.2021.3720

Public-sector Contributions to Novel Biologic Drugs

JAMA Intern Med. 2021 Nov 1;181(11):1522-1525. doi: 10.1001/jamainternmed.2021.3720.

Authors

Rahul K Nayak^{1

2

3}, ChangWon C Lee^{1

2}, Jerry Avorn^{1

2}, Aaron S Kesselheim^{1

2}

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
² Harvard Medical School, Boston, Massachusetts.
³ Department of Medicine, Massachusetts General Hospital, Boston.

Abstract

This cohort study investigates downstream public-sector support for the creation of new biologic drugs by examining their patent and drug development histories.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Biological Products* / economics
Biological Products* / pharmacology
Drug Approval* / economics
Drug Approval* / methods
Drug Costs
Drug Development* / economics
Drug Development* / methods
Drug and Narcotic Control / economics
Humans
Orphan Drug Production / methods
Public Sector* / economics
Public Sector* / statistics & numerical data
United Kingdom
United States

Substances

Biological Products